{"id":349922,"date":"2023-10-25T00:00:00","date_gmt":"2023-10-25T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concop0001-2023-biopharma-dry-and-wet-age-related-macular-degeneration-geographic-focus-china-dry-and\/"},"modified":"2026-04-30T23:28:40","modified_gmt":"2026-04-30T23:28:40","slug":"concop0001-2023-biopharma-dry-and-wet-age-related-macular-degeneration-geographic-focus-china-dry-and-wet-age-related","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concop0001-2023-biopharma-dry-and-wet-age-related-macular-degeneration-geographic-focus-china-dry-and-wet-age-related\/","title":{"rendered":"Dry and Wet Age-Related Macular Degeneration &#8211; Geographic Focus: China &#8211; Dry and Wet Age-Related Macular Degeneration &#8211; China In-Depth (China)"},"content":{"rendered":"<div>\n<p>Age-related macular degeneration (<abbr title=\"age-related macular degeneration\">AMD<\/abbr>), which includes dry and wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr>, is a leading cause of irreparable vision loss globally. In China, patients with wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> are typically treated with <abbr title=\"vascular endothelial growth factor\">VEGF<\/abbr> inhibitors (e.g., Lang Mu [conbercept], Lucentis [ranibizumab], Avastin [bevacizumab], Eylea [aflibercept]). These branded drugs will face competition from the multiple biosimilars of ranibizumab and aflibercept, which are set to enter the Chinese market during the forecast period. Moreover, several potentially more attractive drugs are in development, including Roche\u2019s Vabysmo (faricimab), Novartis\u2019s Beovu (brolucizumab), Regeneron\u2019s high-dose aflibercept, and RemeGen\u2019s RC-28E. Some of these agents may offer a dosing advantage over current agents. In contrast to the treatment of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr>, the treatment of dry <abbr title=\"age-related macular degeneration\">AMD<\/abbr> is limited because no prescription therapies are approved or are in the pipeline for this large subpopulation.<\/p>\n<\/div>\n<div>\n<p>Questions answered<\/p>\n<\/div>\n<ul class=\"BulletListStyle1 BCX0 SCXP178382661 round-bullets\">\n<li>How large is China\u2019s treatment-eligible <abbr title=\"age-related macular degeneration\">AMD<\/abbr> population?<\/li>\n<li>What are the key unmet needs in the management of <abbr title=\"age-related macular degeneration\">AMD<\/abbr>?<\/li>\n<li>How will the wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> treatment algorithm change as new products launch?<\/li>\n<li>How will market dynamics be impacted by the launch of biosimilars of Lucentis and Eylea?<\/li>\n<li>What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<div>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Geographies: China.<\/p>\n<p>Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys of 50 ophthalmologists<\/p>\n<p>Epidemiology: Total, diagnosed, and drug-treated prevalent cases of dry and wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> in urban and rural China.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions<\/p>\n<p>Emerging therapies for wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr>: Phase 3\/<abbr title=\"preregistered\">PR<\/abbr>: 5+ drugs; Phase 1\/2: 10+ drugs.<\/p>\n<p><strong>Product description<\/strong><\/p>\n<\/div>\n<div>\n<p>China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.<\/p>\n<\/div>\n","protected":false},"template":"","class_list":["post-349922","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/349922","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/349922\/revisions"}],"predecessor-version":[{"id":389147,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/349922\/revisions\/389147"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=349922"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}